Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

The drug combination was safe and showed promise in treating advanced tumors.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

The FDA approved a new Pfizer drug for hair loss in teens.

Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.

Erlotinib can cause nonscarring hair loss and itchy skin.

Erlotinib can cause hair loss as a side effect.

SSRIs can cause hair loss, especially sertraline, with higher risk in women.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Idiopathic hirsutism may be linked to increased skin enzyme activity, and new treatments like laser and eflornithine cream show promise.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

The committee decided not to approve the drug due to low effectiveness and high risks.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Including androgens in hormone therapy may lower breast cancer risk.

Generic Palbociclib is safe and tolerable for treating certain breast cancer types.